ACCPL
Start SIP
Invest Now
Start SIP in ACCPL
Performance
- Low
- ₹69
- High
- ₹69
- 52 Week Low
- ₹54
- 52 Week High
- ₹103
- Open Price₹69
- Previous Close₹71
- Volume2,400
- 50 DMA₹73.07
- 100 DMA₹72.92
- 200 DMA-
Investment Returns
- Over 1 Month + 6.86%
- Over 3 Month -15.59%
- Over 6 Month + 14.64%
- Over 1 Year -32.18%
Smart Investing Starts Here Start SIP with Accretion Pharmaceuticals for Steady Growth!
Accretion Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 11.2
- PEG Ratio
- -
- Market Cap Cr
- 76
- P/B Ratio
- 1.6
- Average True Range
- 2.35
- EPS
- 6.11
- Dividend Yield
- 0
- MACD Signal
- -2.52
- RSI
- 44.28
- MFI
- 74.71
Accretion Pharmaceuticals Financials
Accretion Pharmaceuticals Technicals
EMA & SMA
Current Price
₹68.50
-2.5
(-3.52%)
- Bearish Moving Average 12
- Bullish Moving Average 2
- 20 Day
- ₹69.91
- 50 Day
- ₹73.07
- 100 Day
- ₹72.92
- 200 Day
- -
Resistance and Support
68.5
- R3 68.50
- R2 68.50
- R1 68.50
- S1 68.50
- S2 68.50
- S3 68.50
Accretion Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2025-11-14 | Quarterly Results | |
| 2025-06-10 | Audited Results & Others | To consider Other business matters. |
Accretion Pharmaceuticals F&O
About Accretion Pharmaceuticals
- NSE Symbol
- ACCPL
- BSE Symbol
- Managing Director
- Mr. Vivek Ashok Kumar Patel
- ISIN
- INE0T8T01010
Similar Stocks to Accretion Pharmaceuticals
Accretion Pharmaceuticals FAQs
Accretion Pharmaceuticals share price is ₹68 As on 23 February, 2026 | 06:47
The Market Cap of Accretion Pharmaceuticals is ₹76.1 Cr As on 23 February, 2026 | 06:47
The P/E ratio of Accretion Pharmaceuticals is 11.2 As on 23 February, 2026 | 06:47
The PB ratio of Accretion Pharmaceuticals is 1.6 As on 23 February, 2026 | 06:47
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.